No CV safety signals with fremanezumab treatment for migraine
04 Jun 2020
Patients using the CGRP* blocker fremanezumab for migraine treatment need not worry about cardiovascular (CV) safety of the drug, as pooled data from three phase III trials showed no safety signals for CV events with the treatment, even in those with a CV medical history.
Empagliflozin’s cardiovascular benefits lead the change in T2D treatment paradigm
11 May 2020;
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
possible
mechanisms for its cardiovascular benefits.
Sign Out
